Office of the Commissioner/Office of Special Health Issues (OSHI) Records Related to Jan 2013 Mefloquine Meeting

To Whom It May Concern:

This is a request under the Freedom of Information Act. I hereby request the following records:

Records from the Office of the Commissioner/Office of Special Health Issues (OSHI) related to the “mefloquine meeting” held January 11, 2013 at the FDA Center for Drug Evaluation and Research, White Oak Campus, 10903 New Hampshire Avenue, Building 22, Silver Spring, MD 20993, to include any agendas, presentations, internal memoranda, and executive summaries produced from July 2012 through July 2013, during preparation for or as a result of the meeting.

I also request that, if appropriate, fees be waived as I am a representative of a noncommercial scientific institution and believe this request is in the public interest. The requested documents will be made available to the general public free of charge as part of the public information service at MuckRock.com, processed by a representative of the news media/press and is made in the process of news gathering and educational activities and not for commercial usage.

In the event that fees cannot be waived, I would be grateful if you would inform me of the total charges in advance of fulfilling my request. I would prefer the request filled electronically, by e-mail attachment if available or CD-ROM if not.

Thank you in advance for your anticipated cooperation in this matter. I look forward to receiving your response to this request within 20 business days, as the statute requires.

Sincerely,

Dr. Remington Nevin

To Whom It May Concern:

I wanted to follow up on the following Freedom of Information request, copied below, and originally submitted on Feb. 1, 2015. Please let me know when I can expect to receive a response, or if further clarification is needed.

Thank you for your help.

To Whom It May Concern:

I wanted to follow up on my Freedom of Information request for "Records from the Office of the Commissioner/Office of Special Health Issues (OSHI) related to the “mefloquine meeting” held January 11, 2013 at the FDA Center for Drug Evaluation and Research, White Oak Campus, 10903 New Hampshire Avenue, Building 22, Silver Spring, MD 20993, to include any agendas, presentations, internal memoranda, and executive summaries produced from July 2012 through July 2013, during preparation for or as a result of the meeting", originally submitted on Feb. 1, 2015, which you had assigned reference #2015-892.

Please let me know when I can expect to receive a response, or if further clarification is needed.

Thank you for your help.

Dr. Remington Nevin

To Whom It May Concern:

I wanted to follow up on the following Freedom of Information request, copied below, and originally submitted on Feb. 1, 2015. Please let me know when I can expect to receive a response, or if further clarification is needed. You had assigned it reference number #2015-892.

Thank you for your help.

To Whom It May Concern:

I wanted to follow up on the following Freedom of Information request, copied below, and originally submitted on Feb. 1, 2015. Please let me know when I can expect to receive a response, or if further clarification is needed. You had assigned it reference number #2015-892.

Thank you for your help.